Market Overview

Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline

Share:

Campaign designed to raise awareness of the issue of diarrhea
among people with HIV/AIDS and encourage them to speak with their
healthcare providers

Napo Pharmaceuticals, Inc. (Napo), a human health company developing and
commercializing novel gastrointestinal prescription products from plants
used traditionally in rainforest areas, and a wholly-owned subsidiary of
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), announced today that its "Keep
Your Pants On… Unless You Don't Want To
" (KYPO) campaign was chosen
by Healthline as the "Best HIV-related awareness campaign." The KYPO
campaign highlights the need to recognize and treat diarrhea in people
living with HIV/AIDS.

Healthline, which is the world's fastest growing health information site
and has an audience of more than 65 million readers every month, is
commemorating World AIDS Day by celebrating and honoring the activists,
organizations, and initiatives that help educate and raise awareness
about HIV and AIDS in special and meaningful ways with its annual
HIV Influencer Honors
program. Other awards were given by Healthline
to notable HIV campaigns by U=U, Let's Kick ASS, HIV.gov, and POZ.

"I am elated the team responsible for developing our impactful ‘Keep
Your Pants On' campaign has been recognized by Healthline. We remain
dedicated to serving the HIV and AIDS community as we work diligently to
raise awareness among those affected by disease-related diarrhea,"
stated Lisa Conte, Jaguar's president and CEO. "It is our mission to
provide access to Mytesi® to all patients living with HIV and
AIDS suffering from diarrhea as well as educating their healthcare
providers about this first-in-class product and its novel mechanism of
action."

The initial concept for the KYPO campaign was developed by Sari Kimbell,
Founder and Chief Cultivator at Cultivate Consulting. KYPO was first
launched to 10,000 participants during the AIDS Walk Los Angeles event
on October 15, 2017. Campaign participants are encouraged to use the
hashtag #KeepYourPantsOn when posting photos and videos to social media.

Launched by Napo in October 2016, Mytesi® is the only
antidiarrheal studied in and U.S. FDA-approved for the symptomatic
relief of noninfectious diarrhea in adults living with HIV/AIDS on
antiretroviral therapy (ART). Mytesi® is a prescription
treatment for diarrhea that works differently, by acting locally in the
GI tract to normalize the flow of water. Mytesi® does not
have drug-drug interactions with ART and has side effects that are
similar to placebo.

To view the "Keep Your Pants On" campaign, click here: https://keep-your-pants-on.com.

To learn more about what you can do about HIV/AIDS-related diarrhea,
visit www.mytesi.com.

About Mytesi®

Mytesi® (crofelemer) is an antidiarrheal indicated for the
symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not
indicated for the treatment of infectious diarrhea. Rule out infectious
etiologies of diarrhea before starting Mytesi®. If infectious
etiologies are not considered, there is a risk that patients with
infectious etiologies will not receive the appropriate therapy and their
disease may worsen. In clinical studies, the most common adverse
reactions occurring at a rate greater than placebo were upper
respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%),
flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the Amazon rainforest. Napo has
established a sustainable harvesting program for crofelemer to ensure a
high degree of quality and ecological integrity.

About Napo Pharmaceuticals, Inc.

San Francisco-based Napo Pharmaceuticals, Inc. (Napo), focuses on
developing and commercializing proprietary human gastrointestinal
pharmaceuticals for the global marketplace from plants used
traditionally in rainforest areas. Napo is a wholly-owned subsidiary of
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals
company focused on developing novel, sustainably derived
gastrointestinal products for both human prescription use and animals on
a global basis.

For more information about Napo, please visit napopharma.com.
For more information about Jaguar, visit jaguar.health.

Jaguar-JAGX

View Comments and Join the Discussion!
 

Partner Center